← ANALYST RATINGS · TIPRANKS

Lifecore Biomedical (LFCR): analyst forecast and price target

$6.38 −0.93% close 16.10.26 · market cap $244M · Healthcare · Drug Manufacturers - Specialty & Generic IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

0 Buy4 Hold0 Sell

Ratings of 4 analysts in the last 3 months · top analysts only

12-month forecast

$6.28−1.6% downside

Based on 4 price targets given in the last 3 months, the average target is $6.28, the highest $6.28, the lowest $6.28. The average is −1.6% from the last price of $6.38.

$4.00$6.00$8.00Jan 26AprJulOctJan 27AprJulOctHigh$6.28Average$6.28Low$6.28
Highest target $6.28 Average target $6.28 Lowest target $6.28
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% William Blair — Hold — Downgrade 03.10.26on TipRanks Oct 5 05:10 −1.0%next day −1.6% · 5 days −1.6%
Michael Petusky★★★★★★★★★★#4246 · hits 45% · avg +2.3% Barrington — Hold — Downgrade 29.09.26on TipRanks 07:45 +1.3%next day +0.1% · 5 days −4.1%
Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% Craig-Hallum $6.28 Hold −1.6% Downgrade 29.09.26on TipRanks Sep 28 14:05 +56.0%next day +1.3% · 5 days −1.2%
Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% KeyBanc — Hold — Reiterated 06.08.26on TipRanks 04:16 +9.2%next day +2.9% · 5 days −3.5%
Steven Etoch★★★★★★★★★★#2413 · hits 86% · avg +59.3% Stephens $8.50 → $5.00−41.2% Hold −21.6% Reiterated 17.03.26on TipRanks 10:00 −0.4%next day −3.4% · 5 days −5.9%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.28 at a price of $6.58 (−4.6%); now: $6.28 at $6.38 (−1.6%).

$4.00$5.00$6.00Sep 15Oct 1Oct 15Top analysts$6.28Average target$6.28Price$6.38

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

0510174Oct 25164Nov163Dec63Jan 2631Feb261Mar251Apr371May16Jun16Jul71Aug53Sep45Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy311000
Buy766754
Hold100135
Sell000000

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Lifecore Biomedical
  • CEO: Paul Josephs
  • Employees: 382
  • 3515 Lyman Boulevard, Chaska, MN, 55318, US
  • www.lifecore.com

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Data from the stock’s TipRanks forecast page, read 18 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗